Mixed options sentiment in ImmunityBio (IBRX), with shares down $1.02 near $8.97. Options volume roughly in line with average with 58k contracts traded and calls leading puts for a put/call ratio of 0.32, compared to a typical level near 0.26. Implied volatility (IV30) dropped 19.18 near 122.75,in the top quartile of the past year, suggesting an expected daily move of $0.69. Put-call skew flattened, suggesting a modestly bullish tone.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio price target raised to $12 from $7 at Piper Sandler
- ImmunityBio: Advancing ANKTIVA Into a Global, Multi-Indication Immunotherapy Platform Supporting a Buy Rating and $15 Target
- IBRX Earnings this Week: How Will it Perform?
- ImmunityBio completes enrollment of Anktiva trial
- ImmunityBio price target raised to $15 from $10 at H.C. Wainwright